Company Overview and News

KLCI seen trading range bound, hurdle at 1,790

2018-10-07 theedgemarkets
KUALA LUMPUR (Oct 8): Sentiment at the local market is seen dampened today, tracking the slump at most global markets last Friday, and the FBM KLCI is expected to trade range bound with hurdle at 1,790 points.
0049 0008 8664 7374

Inta Bina, Oceancash, EA Technique, MHB, MyEG, S P Setia, SimeProp, Tien Wah, Willowglen and Zelan

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): Based on corporate announcements and news flow today, companies that may be in focus on Monday (Oct 8) may include the following: Inta Bina Group Bhd, Oceancash Pacific Bhd, EA Technique Bhd, Malaysia Marine Heavy Engineering Holdings Bhd, My EG Services Bhd, S P Setia Bhd, Sime Darby Property Bhd, Tien Wah Press Holdings Bhd, Willowglen MSC Bhd and Zelan Bhd.
0049 0008 8664 DONGY BSMAF 7374 1818

Inta Bina, Oceancash get SC's nod for Main Market transfer

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): Just over a year after its debut in Bursa Malaysia's ACE Market, construction player Inta Bina Group Bhd has obtained the green light from the Securities Commission Malaysia to transfer its listing to the Main Market.
0049 BSMAF 1818

Stock With Momentum: Oceancash Pacific

2018-06-20 theedgemarkets
SHARES in resinated felt and non-woven fabric maker Oceancash Pacific Bhd (fundamental: 2.8/3, valuation: 0.8/3) triggered our proprietary momentum algorithm yesterday for the first time this year.

Oceancash plans new production line in Thailand

PETALING JAYA: The country’s biggest feltmaker, Oceancash Pacific Bhd , is said to be considering a plan to relocate part of its production capacity to Thailand, the group’s fastest-growing market.
0049 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...